Intervention
Canagliflozin (JNJ-28431754)
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownCANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideNCT00968812 · 2009-09-01
COMPLETEDA Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have DiabetesNCT00650806 · 2008-05-01
COMPLETEDAn Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesNCT00642278 · 2008-04-01
COMPLETEDStudy to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese VolunteersNCT01756404 · 2007-06-14
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED4
Phase mix
PHASE22
PHASE11
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.